DailyStocks.com

Sign up   Log In
Lost Password?
MyDailyStocks
Set Home Page
What's New
Site Map
Help
FAQ
  
GLOSSARY STOCK ANALYSIS INSIDER BUYS PRODUCT REVIEWS EDUCATION SEARCH
Symbol:
Bookmark and Share

MARKET WATCH
DayTrading Portal
Free Stock Charts
Free Technical Analysis
REVIEWS
Online Brokers Review 2014
Investors Daily
Top 20 Baby Boomer WebSites
SEARCH ENGINES
Online Courses
Financial Advisers
SEC filings
Finance Jobs
Brand Reviews Only
Start-up Content Only

Bartosiak: Trading Tesla's (TSLA) Earnings with Options
Join Dave Bartosiak at 1:00pm Central Time on Tuesday, February 21st, to see his thoughts on Tesla (TSLA) before they report earnings with real-time options insight.
3 Surging Growth Stocks for Your Portfolio
3 Surging Growth Stocks for Your Portfolio
Can Trump Alone Save the Struggling Coal Industry?
Jittery developments in key global markets and higher production countries like Australia and Indonesia, and, importantly, a stronger greenback, are making the export market fiercely competitive for the U.S. coal players.
Retail in Focus as Q4 Earnings Season Winds Down
Retail sector stocks have lagged the broader market since the November elections.
When "Insider" Greed Is Good
Not all insider buys are made equal. But when you focus on the right ones, the reward can be tremendous.
A Beginner's Guide to Investing in China
In a special edition of the Zacks Friday Finish Line, Content Writer Ryan McQueeney and Editor Maddy Johnson are joined by Brendan Ahern, the Chief Investment Officer at KraneShares.
Five Major Myths about Options Trading
These are the five biggest myths about options trading
Mylan's Proposed Biosimailar for Cancer Under Review in U.S.
Mylan N.V. (MYL) and Biocon Ltd. announced that the FDA has accepted their biologics license application for a biosimilar version of Amgen's (AMGN) Neulasta (pegfilgrastim) - MYL-1401H.
Moody's Jumps into Action as Aetna-Humana Deal Fails
After the merger deal between Aetna Inc. (AET) and Humana Inc. (HUM) fell through, rating agency Moody's Investors Service jumped into action
Merrimack (MACK): What Awaits the Stock in Q4 Earnings?
Merrimack Pharmaceuticals, Inc. (MACK) is scheduled to report fourth-quarter 2016 results in the next week. Last quarter, Merrimack delivered a positive earnings surprise of 23.33%.


Content Library
News
Insider Buys and Activist Buys
RESEARCH
Stock Search Engine
Guide to Financial Sites
FAQ
Investors Research Portal
Glossary
Company Overviews
Forums
Work with DailyStocks
License our Glossary
Write for us
About us
Feedback
Partners & Sponsors
InvestingChannel
COPYRIGHT© 1997-2012 DailyStocks. All Rights Reserved. Privacy Policy.
Link to this page http://www.dailystocks.com/zacks_category.php, notify us and we will consider your web site to our directory